Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT07163624
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.
Interventions
Name:
UBT251 Injection 2.0 mg and UBT251 Injection Placebo
Type:
DRUG
Description:
UBT251 Injection and UBT251 Injection Placebo once weekly
Name:
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo
Type:
DRUG
Description:
UBT251 Injection and UBT251 Injection Placebo once weekly
Name:
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo
Type:
DRUG
Description:
UBT251 Injection and UBT251 Injection Placebo once weekly
Name:
UBT251 Injection 6.0 mg and UBT251 Injection Placebo
Type:
DRUG
Description:
UBT251 Injection and UBT251 Injection Placebo once weekly
Name:
Semaglutide Injection (OzempicĀ®)
Type:
DRUG
Description:
Semaglutide Injection (OzempicĀ®) once weekly
Primary Outcomes
Measure:
Change From Baseline in HbA1c at Week 24
TimeFrame:
Baseline to week 24
Description:
HbA1c was obtained at baseline and at Week 24
Trial Information
NCT ID
NCT07163624
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
The United Bio-Technology (Hengqin) Co., Ltd.
Last Updated
December 15, 2025